Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. J of Skin [Internet]. 2020 Sep. 2 [cited 2026 May 22];4(5):s31. Available from: https://skin.dermsquared.com/skin/article/view/980